目前傳統(tǒng)的心臟毒性評價(jià)指標(biāo)乳酸脫氫酶(LDH)、門冬氨酸氨基轉(zhuǎn)移酶(AST)、肌酸激酶(CK)以及肌酸激酶同工酶(CK-MB)等在早期毒性評價(jià)中均有局限性,因此急需靈敏度高、特異性強(qiáng)的生物標(biāo)記物進(jìn)行早期心臟毒性評價(jià).隨著基因組學(xué)、轉(zhuǎn)錄組學(xué)、蛋白質(zhì)組學(xué)和代謝組學(xué)的不斷發(fā)展,評價(jià)藥物早期心臟毒性生物標(biāo)記物的研究也有了新的進(jìn)展.對基因類、蛋白類以及代謝小分子類心臟毒性生物標(biāo)記物的研究進(jìn)展加以綜述,為進(jìn)一步對早期心臟毒性生物標(biāo)記物的研究提供更好的理論支持.

The traditional evaluation indexes of cardiotoxicity [lactate dehydrogenase (LDH), aspartate transaminase (AST), creatine kinase (CK), and creatine kinase isoenzymes (CK-MB)] in early toxicity evaluation has limitations, so it is urgent to need high sensitivity, specificity of biomarkers for toxicity evaluation in the early stage of cardiotoxicity. With the development of genomics, transcriptomics, proteomics, and metabolomics, the continuous development of the biomarkers for early prediction of cardiotoxicity also get new progress. This study was reviewed from the progress of the biomarkers for early prediction of cardiotoxicity in gene, protein and small molecule metabolism, in order to provide better theoretical support for the study of the biomarkers for early prediction of cardiotoxicity.

國家自然科學(xué)基金資助項(xiàng)目(81273998)